Nicolas Gendron on Sustainability in Anticoagulation and DOACs
Nicolas Gendron, Research Fellow, Hematologist at Boston Children’s Hospital, shared on LinkedIn:
”Anticoagulation and sustainability. What is the carbon impact of DOACs?
Our study, published in Haematologica Journal, compares for the first time the carbon footprint of the three DOACs used in France (dabigatran, apixaban, rivaroxaban) using two life cycle analysis databases, Ecovamed and MCF.
The main findings:
- DOACs do not have the same carbon footprint, despite similar efficacy and safety.
- Dabigatran has a much higher carbon impact than anti-Xa drugs (apixaban and rivaroxaban), with a footprint that is 3 to 36 times higher depending on the indications and databases.
- Most of dabigatran’s impact comes from its active ingredient, which is very energy-intensive to produce.
- Conversely, for apixaban and rivaroxaban, nearly 70% of the carbon impact is linked to corporate activities (RandD, distribution, administration, etc.).
- Lower doses, used for prolonged treatments, significantly reduce emissions.
DOACs are among the most widely prescribed drugs in the world.
At a time when the healthcare system needs to reduce its environmental footprint, these results show that, given equivalent efficacy and safety, the choice of treatment can have a major environmental impact.
Our study advocates for integrating environmental criteria into treatment decisions whenever possible, without ever compromising the quality of care.
Proud of this collective work.
Well done Laurence Chery, Zahra Hassani, Lise Durand, Dorothee Boisseau, Victorien Monguillon, David Grimaldi, Sebastien Taillemite, and Benjamin de Sainte Marie.
Thank you to Ecovamed for providing access to their high-quality data.
Thank you to SESAME.
Let’s continue to move towards cutting-edge, low-carbon medicine.”
Read the full article here.
Article: Carbon footprint of direct oral anticoagulants in atrial fibrillation and venous thromboembolism
Authors: Laurence Chery, Zahra Hassani, Lise Durand, Dorothee Boisseau, Victorien Monguillon, David Grimaldi, Sebastien Taillemite, Benjamin de Sainte Marie, Nicolas Gendron
Stay updated on all scientific advances with Hemostasis Today.
-
Jan 13, 2026, 13:03Claudio Laudani on Dual Versus Single Antiplatelet Therapy
-
Jan 13, 2026, 12:46Stephanie Carlin and Colleagues on Clinical Outcomes of DOAC-Anticonvulsant Coprescription
-
Jan 13, 2026, 10:53Lena Volland on Ming Y Lim’s Example of Designing Care Models for WGBD Community With Intention
-
Jan 13, 2026, 05:05Pablo Corral Shares Key Takeaways on Reducing LDL-Cholesterol to Very Low Levels
-
Jan 13, 2026, 04:49Martin Haluzík Shares A Study on GLP1-1RAs Use in Peripheral Artery Disease and DM
-
Jan 13, 2026, 04:37Shreya Agarwal and Bryce A Kerlin on The Impact of Advanced Hemostasis and Thrombosis Fellowship Trainings
-
Jan 13, 2026, 03:53Christian Schulze Shares New Data from DANGERSHOCK
-
Jan 13, 2026, 03:39Samwel Mikaye Breaks Down Peripheral Blood Smear
-
Jan 12, 2026, 20:15Mazou Ngou Temgoua on SCAF: Subclinical Atrial Fibrillation on Treatment with Apixaban or Aspirin